Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03795012 |
Recruitment Status :
Terminated
(Slow recruitment rate)
First Posted : January 7, 2019
Last Update Posted : August 31, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: Eribulin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Phase II Trial Evaluating the Efficacy of Eribulin Monotherapy and Eribulin Plus Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients After Progression on Endocrine Therapy (REVERT) |
Actual Study Start Date : | April 30, 2019 |
Actual Primary Completion Date : | March 31, 2021 |
Actual Study Completion Date : | March 31, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Eribulin monotherapy
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
|
Drug: Eribulin
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
Other Name: Halaven |
Active Comparator: eribulin plus endocrine therapy
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
|
Drug: Eribulin
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
Other Name: Halaven |
- The overall response rate (ORR) [ Time Frame: Baseline up to 27 months ]The overall response rate (ORR) in the eribulin + ET arms, defined as the proportion of patients with best overall response of confirmed complete response or partial response based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- The progression-free survival (PFS) [ Time Frame: Baseline up to 27 months ]The progression-free survival (PFS) for patients treated with endocrine therapy alone or in combination with eribulin is defined as the time from randomization until death by any cause or objective tumor progression based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- PFS-2, in the eribulin and the eribulin + ET arms [ Time Frame: Baseline up to 27 months ]The PFS-2, in the eribulin and the eribulin + ET arms, defined as the time from the randomization to the second disease progression or death, i.e., PFS after the next line of treatment, based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- Overall response rate (ORR) in the eribulin arm [ Time Frame: Baseline up to 27 months ]The overall response rate (ORR) in the eribulin arm, defined as the proportion of patients with best overall response of confirmed complete response or partial response based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- The duration of response (DOR) in the eribulin and the eribulin + ET arms [ Time Frame: Baseline up to 27 months ]The duration of response (DOR) in the eribulin and the eribulin + ET arms, defined as the time from the start of the treatment to disease progression based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- The clinical benefit rate (CBR) in the eribulin and the eribulin + ET arms [ Time Frame: Baseline up to 27 months ]The clinical benefit rate (CBR) in the eribulin and the eribulin + ET arms, defined as the proportion of patients with no disease progression after 6 months of therapy, based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11.
- The overall survival (OS) in the eribulin and the eribulin + ET arms [ Time Frame: Baseline up to 27 months ]The overall survival (OS) in the eribulin and the eribulin + ET arms, defined as the length of time that patients remain alive from the start of treatment (OS will be collected at the end of the study).
- Maximum Tumor shrinkage [ Time Frame: Baseline up to 27 months ]Maximum Tumor shrinkage, defined as the percentage of tumor shrinkage from baseline (obtained from the sum of the largest diameters of the target lesions), based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)1.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ER-positive and/or PR-positive breast cancer.
- HER2-negative breast cancer.
- Unresectable locally advanced or metastatic breast cancer.
- Confirmed disease progression while in the last aromatase inhibition-containing regimen in the metastatic setting.
- At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting.
- Patients with no prior line of chemotherapy in the metastatic setting.
- At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting.
- ECOG score 0 or 1.
- Patients have adequate bone marrow and organ function.
- Patients must have measurable disease (RECIST v.1.1).
- Premenopausal with LHRH analogues for at least 28 days) and postmenopausal women.
- Patients must agree to not breastfeed during the study and for 3 months after the last dose of study treatment.
- Life expectancy greater or equal to 12 weeks.
- Patients agree to collection of blood samples (liquid biopsy) and optional collection of metastatic tumour sample (biopsy) at the time of inclusion and progression (if appropriate).
Exclusion Criteria:
- Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities.
- Have received prior chemotherapy for locally advanced or metastatic disease.
- Have peripheral neuropathy grade 2 or greater.
- QTc > 480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders
- Child-bearing potential women not using highly effective methods of contraception.
- Known hypersensitivity to eribulin, endocrine therapy or its excipients.
- Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast.
- Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease.
- Have a serious concomitant systemic disorder incompatible with the study.
- Major surgical procedure or significant traumatic injury within 28 days prior to randomization.
- Have received any anti-cancer biology or investigational treatment within 30 days prior to randomization.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03795012
Spain | |
Hospital de Jaén | |
Jaen, Jaén, Spain | |
Hospital Quiron Dexeus | |
Barcelona, Please Select, Spain | |
Institut Català d'Oncologia | |
Girona, Spain | |
Complejo Asistencial Universitario de León | |
León, Spain | |
Hospital Ramón y Cajal | |
Madrid, Spain | |
Hospital Universitario La Paz, | |
Madrid, Spain | |
Hospital Son Llatzer | |
Palma De Mallorca, Spain | |
Hospital Universitario Dr Peset | |
Valencia, Spain | |
Hospital Miguel Servet | |
Zaragoza, Spain |
Principal Investigator: | Javier Cortés, PhD | MedSIR |
Responsible Party: | MedSIR |
ClinicalTrials.gov Identifier: | NCT03795012 |
Other Study ID Numbers: |
MedOPP167 2017-004324-30 ( EudraCT Number ) |
First Posted: | January 7, 2019 Key Record Dates |
Last Update Posted: | August 31, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
breast cancer Unresectable ER PR |
Her2 recurrent metastatic |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |